Synthesis and Evaluation of 18F-Enzalutamide, a New Radioligand for PET Imaging of Androgen Receptors: A Comparison with 16{beta}-18F-Fluoro-5{alpha}-Dihydrotestosterone

Conclusion: Despite its lower apparent molar activity, 18F-enzalutamide shows higher tumor uptake and better metabolic stability than 18F-FDHT and thus seems to have more favorable properties for imaging of AR with PET. However, further evaluation in other oncologic animal models and patients is warranted to confirm these results.

Source: Journal of Nuclear Medicine - July 30, 2021 Category: Nuclear Medicine Authors: Antunes, I. F., Dost, R. J., Hoving, H. D., van Waarde, A., Dierckx, R. A. J. O., Samplonius, D. F., Helfrich, W., Elsinga, P. H., de Vries, E. F. J., de Jong, I. J. Tags: Featured Article of the Month Source Type: research